8. Obesity Management for the Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes—2019
暂无分享,去创建一个
[1] S. Haneuse,et al. Microvascular Outcomes in Patients With Diabetes After Bariatric Surgery Versus Usual Care , 2018, Annals of Internal Medicine.
[2] Jung-Han Kim,et al. Stereotactic Core-Needle Biopsy of Non-Mass Calcifications: Outcome and Accuracy at Long-Term Follow-Up , 2003, Korean journal of radiology.
[3] A. Aminian,et al. ASMBS updated position statement on bariatric surgery in class I obesity (BMI 30-35 kg/m2). , 2018, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.
[4] J. Hjelmesæth,et al. Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities , 2018, JAMA.
[5] B. Wolfe,et al. Seven-Year Weight Trajectories and Health Outcomes in the Longitudinal Assessment of Bariatric Surgery (LABS) Study , 2017, JAMA surgery.
[6] Roy Taylor,et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial , 2017, The Lancet.
[7] G. Fernández-Ranvier,et al. Preoperative insulin therapy as a marker for type 2 diabetes remission in obese patients after bariatric surgery. , 2017, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.
[8] Shelby Sullivan. Endoscopic Medical Devices for Primary Obesity Treatment in Patients With Diabetes , 2017, Diabetes Spectrum.
[9] K. Fujioka,et al. Obesity Pharmacotherapy in Patients With Type 2 Diabetes , 2017, Diabetes Spectrum.
[10] James H. Faghmous,et al. Targeting weight loss interventions to reduce cardiovascular complications of type 2 diabetes: a machine learning-based post-hoc analysis of heterogeneous treatment effects in the Look AHEAD trial. , 2017, The lancet. Diabetes & endocrinology.
[11] K. Truong,et al. The Long-Term Effects of Bariatric Surgery on Type 2 Diabetes Remission, Microvascular and Macrovascular Complications, and Mortality: a Systematic Review and Meta-Analysis , 2017, Obesity Surgery.
[12] Raymond L. Forbes,et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial , 2017, The Lancet.
[13] L. Genser,et al. Bariatric surgery versus intensive medical therapy for diabetes -5- year outcomes , 2017 .
[14] P. O’Brien,et al. Five-Year Outcomes of a Randomized Trial of Gastric Band Surgery in Overweight but Not Obese People With Type 2 Diabetes , 2017, Diabetes Care.
[15] V. Montori,et al. Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. , 2017, JAMA.
[16] C. Burant,et al. Impact of weight loss on waist circumference and the components of the metabolic syndrome , 2017, BMJ Open Diabetes Research and Care.
[17] L. Ji,et al. Baseline Body Mass Index and the Efficacy of Hypoglycemic Treatment in Type 2 Diabetes: A Meta-Analysis , 2016, PloS one.
[18] W. Herman,et al. Reconciliation of Type 2 Diabetes Remission Rates in Studies of Roux-en-Y Gastric Bypass , 2016, Diabetes Care.
[19] P. Schauer,et al. The Socioeconomic Impact of Morbid Obesity and Factors Affecting Access to Obesity Surgery. , 2016, The Surgical clinics of North America.
[20] Avis J. Thomas,et al. Durability of Addition of Roux-en-Y Gastric Bypass to Lifestyle Intervention and Medical Management in Achieving Primary Treatment Goals for Uncontrolled Type 2 Diabetes in Mild to Moderate Obesity: A Randomized Control Trial , 2016, Diabetes Care.
[21] F. Rubino,et al. Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations , 2016, Diabetes Care.
[22] F. Rubino,et al. Identifying Barriers to Appropriate Use of Metabolic/Bariatric Surgery for Type 2 Diabetes Treatment: Policy Lab Results , 2016, Diabetes Care.
[23] R. Eckel,et al. Clinical Outcomes of Metabolic Surgery: Microvascular and Macrovascular Complications , 2016, Diabetes Care.
[24] B. Wolfe,et al. Clinical Outcomes of Metabolic Surgery: Efficacy of Glycemic Control, Weight Loss, and Remission of Diabetes , 2016, Diabetes Care.
[25] P. Schauer,et al. Bariatric Surgery in Obese Patients With Type 1 Diabetes , 2016, Diabetes Care.
[26] Benjamin Aribisala,et al. Very Low-Calorie Diet and 6 Months of Weight Stability in Type 2 Diabetes: Pathophysiological Changes in Responders and Nonresponders , 2016, Diabetes Care.
[27] D. Flum,et al. Gastric bypass surgery vs intensive lifestyle and medical intervention for type 2 diabetes: the CROSSROADS randomised controlled trial , 2016, Diabetologia.
[28] D. Redelmeier,et al. Self-harm Emergencies After Bariatric Surgery: A Population-Based Cohort Study. , 2016, JAMA surgery.
[29] F. Rubino,et al. Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: a Joint Statement by International Diabetes Organizations , 2016, Obesity Surgery.
[30] M. Talamini,et al. Lap band outcomes from 19,221 patients across centers and over a decade within the state of New York , 2016, Surgical Endoscopy.
[31] Chih-Cheng Hsu,et al. Effect of Bariatric Surgery vs Medical Treatment on Type 2 Diabetes in Patients With Body Mass Index Lower Than 35: Five-Year Outcomes. , 2015, JAMA surgery.
[32] F. Rubino,et al. Bariatric–metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial , 2015, The Lancet.
[33] J. Boucher,et al. Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials. , 2015, Journal of the Academy of Nutrition and Dietetics.
[34] R. DeFronzo,et al. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. , 2015, JAMA.
[35] J. Clark,et al. Prevalence of and risk factors for hypoglycemic symptoms after gastric bypass and sleeve gastrectomy , 2015, Obesity.
[36] N. Nguyen,et al. Use and Outcomes of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Gastric Bypass: Analysis of the American College of Surgeons NSQIP. , 2015, Journal of the American College of Surgeons.
[37] E. Mayer-Davis,et al. Partial meal replacement plan and quality of the diet at one year: Action for Health in Diabetes (Look AHEAD) Trial , 2015 .
[38] Markku Peltonen,et al. Incidence and remission of type 2 diabetes in relation to degree of obesity at baseline and 2 year weight change: the Swedish Obese Subjects (SOS) study , 2015, Diabetologia.
[39] S. Bleich,et al. Efficacy of commercial weight-loss programs: an updated systematic review. , 2015, Annals of internal medicine.
[40] S. Kahn,et al. Optimum BMI Cut Points to Screen Asian Americans for Type 2 Diabetes , 2015, Diabetes Care.
[41] P. Schauer,et al. How safe is metabolic/diabetes surgery? , 2015, Diabetes, obesity & metabolism.
[42] V. Montori,et al. Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis. , 2015, The Journal of clinical endocrinology and metabolism.
[43] E. Livingston,et al. Association between bariatric surgery and long-term survival. , 2015, JAMA.
[44] Y. Bao,et al. Visceral fat area as a new predictor of short-term diabetes remission after Roux-en-Y gastric bypass surgery in Chinese patients with a body mass index less than 35 kg/m2. , 2015, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.
[45] M. Gulliford,et al. Incidence of type 2 diabetes after bariatric surgery: population-based matched cohort study. , 2014, The lancet. Diabetes & endocrinology.
[46] A. Kyriacou,et al. Time to end medical nihilism in non-surgical weight management , 2014 .
[47] D. Ryan,et al. Weight-Loss Therapy in Type 2 Diabetes: Effects of Phentermine and Topiramate Extended Release , 2014, Diabetes Care.
[48] Kristian Thorlund,et al. Comparison of weight loss among named diet programs in overweight and obese adults: a meta-analysis. , 2014, JAMA.
[49] A. Goldfine,et al. Roux-en-Y gastric bypass surgery or lifestyle with intensive medical management in patients with type 2 diabetes: feasibility and 1-year results of a randomized clinical trial. , 2014, JAMA surgery.
[50] W. Herman,et al. Very-low-energy diet for type 2 diabetes: an underutilized therapy? , 2014, Journal of diabetes and its complications.
[51] Robert F Kushner,et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. , 2014, Journal of the American College of Cardiology.
[52] C. Bouchard,et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. , 2014, JAMA.
[53] Deepak L. Bhatt,et al. Bariatric surgery versus intensive medical therapy for diabetes--3-year outcomes. , 2014, The New England journal of medicine.
[54] R. Henry,et al. Prevention of Type 2 Diabetes in Subjects With Prediabetes and Metabolic Syndrome Treated With Phentermine and Topiramate Extended Release , 2014, Diabetes Care.
[55] John P H Wilding. The importance of weight management in type 2 diabetes mellitus , 2014, International journal of clinical practice.
[56] D. Cummings,et al. Beyond BMI: the need for new guidelines governing the use of bariatric and metabolic surgery. , 2014, The lancet. Diabetes & endocrinology.
[57] A. Schwartz,et al. Eight-Year Weight Losses with an Intensive Lifestyle Intervention: The Look AHEAD Study , 2014, Obesity.
[58] M. Neovius,et al. Effects of anti-obesity drugs, diet, and exercise on weight-loss maintenance after a very-low-calorie diet or low-calorie diet: a systematic review and meta-analysis of randomized controlled trials123 , 2013, The American journal of clinical nutrition.
[59] Luis Garcia,et al. Weight change and health outcomes at 3 years after bariatric surgery among individuals with severe obesity. , 2013, JAMA.
[60] F. Greenway,et al. Effects of Naltrexone Sustained- Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes , 2013, Diabetes Care.
[61] K. Gadde,et al. Evaluation of phentermine and topiramate versus phentermine/topiramate extended‐release in obese adults , 2013, Obesity.
[62] J. Birkmeyer,et al. Surgical skill and complication rates after bariatric surgery. , 2013, The New England journal of medicine.
[63] M. Kroh,et al. Can Diabetes Be Surgically Cured? Long-Term Metabolic Effects of Bariatric Surgery in Obese Patients with Type 2 Diabetes Mellitus , 2013, Annals of surgery.
[64] M. Bessler,et al. Very Low–Calorie Diet Mimics the Early Beneficial Effect of Roux-en-Y Gastric Bypass on Insulin Sensitivity and β-Cell Function in Type 2 Diabetic Patients , 2013, Diabetes.
[65] X. Ouyang,et al. Effect of laparoscopic Roux-en-Y gastric bypass surgery on type 2 diabetes mellitus with hypertension: a randomized controlled trial. , 2013, Diabetes research and clinical practice.
[66] A. Kersting,et al. Risk of completed suicide after bariatric surgery: a systematic review , 2013, Obesity reviews : an official journal of the International Association for the Study of Obesity.
[67] Daniel B. Jones,et al. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient—2013 update: Cosponsored by american association of clinical endocrinologists, The obesity society, and american society for metabolic & bariatric surgery* , 2013, Obesity.
[68] A. Geliebter,et al. Substance use following bariatric weight loss surgery. , 2013, JAMA surgery.
[69] S. Hunt,et al. Health benefits of gastric bypass surgery after 6 years. , 2012, JAMA.
[70] P. O'Neil,et al. Randomized Placebo‐Controlled Clinical Trial of Lorcaserin for Weight Loss in Type 2 Diabetes Mellitus: The BLOOM‐DM Study , 2012, Obesity.
[71] D. Cummings,et al. Effects of Gastric Bypass Surgery in Patients With Type 2 Diabetes and Only Mild Obesity , 2012, Diabetes Care.
[72] G. Bray,et al. Effects of 4 weight-loss diets differing in fat, protein, and carbohydrate on fat mass, lean mass, visceral adipose tissue, and hepatic fat: results from the POUNDS LOST trial. , 2012, The American journal of clinical nutrition.
[73] G. Wakabayashi,et al. IFSO-APC Consensus Statements 2011 , 2012, Obesity Surgery.
[74] C. Bouchard,et al. Bariatric surgery and long-term cardiovascular events. , 2012, JAMA.
[75] S. Haneuse,et al. A Multisite Study of Long-term Remission and Relapse of Type 2 Diabetes Mellitus Following Gastric Bypass , 2012, Obesity Surgery.
[76] Daniel B. Jones,et al. First Report from the American College of Surgeons Bariatric Surgery Center Network: Laparoscopic Sleeve Gastrectomy has Morbidity and Effectiveness Positioned Between the Band and the Bypass , 2011, Annals of surgery.
[77] F. Rubino,et al. IDF's view of bariatric surgery in type 2 diabetes , 2011, The Lancet.
[78] Benjamin S. Aribisala,et al. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol , 2011, Diabetologia.
[79] K. Gadde,et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial , 2011, The Lancet.
[80] Ross Ward,et al. American Association of Clinical Endocrinologists , 2011 .
[81] J. Birkmeyer,et al. Hospital complication rates with bariatric surgery in Michigan. , 2010, JAMA.
[82] F. Rubino,et al. The Diabetes Surgery Summit Consensus Conference: Recommendations for the Evaluation and Use of Gastrointestinal Surgery to Treat Type 2 Diabetes Mellitus , 2010, Annals of surgery.
[83] Donald A Williamson,et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. , 2009, The New England journal of medicine.
[84] N. Nguyen,et al. A Prospective Randomized Trial of Laparoscopic Gastric Bypass Versus Laparoscopic Adjustable Gastric Banding for the Treatment of Morbid Obesity: Outcomes, Quality of Life, and Costs , 2009, Annals of surgery.
[85] S. Woods,et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. , 2009, Nature chemical biology.
[86] B. Wolfe,et al. Perioperative safety in the longitudinal assessment of bariatric surgery. , 2009, The New England journal of medicine.
[87] C. Bouchard,et al. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. , 2009, The Lancet. Oncology.
[88] I. Greenberg,et al. Behavioral and Psychological Care in Weight Loss Surgery: Best Practice Update , 2009, Obesity.
[89] C. Apovian,et al. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, THE OBESITY SOCIETY, AND AMERICAN SOCIETY FOR METABOLIC & BARIATRIC SURGERY MEDICAL GUIDELINES FOR CLINICAL PRACTICE FOR THE PERIOPERATIVE NUTRITIONAL, METABOLIC, AND NONSURGICAL SUPPORT OF THE BARIATRIC SURGERY PATIENT , 2009, Obesity.
[90] Bryan K. Smith,et al. American College of Sports Medicine Position Stand. Appropriate physical activity intervention strategies for weight loss and prevention of weight regain for adults. , 2009, Medicine and science in sports and exercise.
[91] D. Dempsey,et al. Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects , 2008 .
[92] Claude Bouchard,et al. Effects of bariatric surgery on mortality in Swedish obese subjects. , 2007, The New England journal of medicine.
[93] T. Wadden,et al. The Evolution of Very‐Low‐Calorie Diets: An Update and Meta‐analysis , 2006, Obesity.
[94] A. Kaiser. Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. , 2005, The New England journal of medicine.
[95] Claude Bouchard,et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. , 2004, The New England journal of medicine.
[96] C. Nishida,et al. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies , 2004, The Lancet.
[97] 2 nd International DAWN Summit : a call-to-action to improve psychosocial care for people with diabetes , 2004 .
[98] L. Sjöström,et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. , 2004, Diabetes care.
[99] M. Franz,et al. The evidence for the effectiveness of medical nutrition therapy in diabetes management. , 2002, Diabetes care.
[100] S. Fowler,et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .
[101] Roy A Kaplan,et al. Role of Orlistat in the Treatment of Obese Patients With Type 2 Diabetes: A 1-year randomized double-blind study , 1998, Diabetes Care.
[102] B. Goldstein,et al. Beneficial health effects of modest weight loss. , 1992, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.
[103] UK Prospective Diabetes Study 7: response of fasting plasma glucose to diet therapy in newly presenting type II diabetic patients, UKPDS Group. , 1990, Metabolism: clinical and experimental.